IP Barriers Block Pfizer Following US Pegfilgrastim Approval

Sixth Oncology Biosimilar Approval Chalked Up

Pfizer has won the first US Food and Drug Administration biosimilar approval this year, for its Nyvepria (pegfilgrastim-apgf) pre-filled syringes. However, it must overcome intellectual property hurdles before it can roll out the product.

PfizerSign
Pfizer's biosimilar portfolio now includes six FDA-approved oncology products • Source: Shutterstock

More from Biosimilars

More from Products